207 related articles for article (PubMed ID: 28072494)
1. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.
Liu Z; Jiang L; Liang G; Song E; Jiang W; Zheng Y; Gong C
J Viral Hepat; 2017 Jul; 24(7):561-572. PubMed ID: 28072494
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
[TBL] [Abstract][Full Text] [Related]
3. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.
Dai MS; Wu PF; Lu JJ; Shyu RY; Chao TY
Support Care Cancer; 2004 Mar; 12(3):191-6. PubMed ID: 15074316
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
6. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.
Li H; Zhang HM; Chen LF; Chen YQ; Chen L; Ren H; Hu HD
Clin Res Hepatol Gastroenterol; 2015 Feb; 39(1):80-92. PubMed ID: 25199680
[TBL] [Abstract][Full Text] [Related]
8. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Tseng CM; Chen TB; Hsu YC; Chang CY; Lin JT; Mo LR
Asia Pac J Clin Oncol; 2016 Dec; 12(4):421-429. PubMed ID: 27435683
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
13. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
15. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
[TBL] [Abstract][Full Text] [Related]
17. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Loomba R; Rowley A; Wesley R; Liang TJ; Hoofnagle JH; Pucino F; Csako G
Ann Intern Med; 2008 Apr; 148(7):519-28. PubMed ID: 18378948
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
